Journal
CANCER BIOLOGY & THERAPY
Volume 5, Issue 8, Pages 928-932Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.5.8.3251
Keywords
KRAS; colorectal; cancer; mutation; A146
Categories
Funding
- NCI NIH HHS [CA062924, CA121113, P50 CA062924, R01 CA121113] Funding Source: Medline
- Wellcome Trust [077012] Funding Source: Medline
Ask authors/readers for more resources
An activating point mutation in codon 12 of the HRAS gene was the first somatic point mutation identified in a human cancer and established the role of somatic mutations as the common driver of oncogenesis. Since then, there have been over 11,000 mutations in the three RAS (HRAS, KRAS and NRAS) genes in codons 12, 13 and 61 reported in the literature. We report here the identification of recurrent somatic missense mutations at alanine 146, a highly conserved residue in the guanine nucleotide binding domain. In two independent series of colorectal cancers from Hong Kong and the United States we detected KRAS A146 mutations in 7/126 and 2/94 cases, respectively, giving a combined frequency of 4%. We also detected KRAS Al 46 mutations in 2/40 (5%) colorectal cell lines, including the NCI-60 colorectal cancer line HCC2998. Codon 146 mutations thus are likely to make an equal or greater contribution to colorectal cancer than codon 61 mutations (4.2% in our combined series, 1% in the literature). Lung adenocarcinomas and large cell carcinomas did not show codon 146 mutations. We did, however, identify a KRAS Al 46 mutation in the ML-2 acute myeloid leukemia cell line and an NRAS Al 46 mutation in the NALM-6 B-cell acute lymphoblastic leukemia line, suggesting that the contribution of codon 146 mutations is not entirely restricted to colorectal cancers or to KRAS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available